NCCN Guidelines® Insights - Non-Small Cell Lung Cancer, Version 2.2013

These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was a major update for the 2013 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC). The NCCN Guidelines Insights focus on the major updates for the NCCN Guidelines and discuss the new updates in greater detail.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to NCCN Guidelines for NSCLC
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for NSCLC
Additional information
Supporters: 

Supported by educational grants from ARIAD Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.; CELGENE CORPORATION; Eisai Inc.; Endo Pharmaceuticals and HealthTronics; Genentech; Millennium: The Takeda Oncology Company; and Teva Pharmaceuticals

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
06/10/2013
Course expires: 
06/10/2014
Cost:
$0.00

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing